Analyst Reco. GoodRx Holdings, Inc.

Equities

GDRX

US38246G1085

Real-time Estimate Cboe BZX Other stock markets 15:08:04 01/05/2024 BST			5-day change	1st Jan Change
7.01 ^USD	-1.27%		+1.58%	+5.52%

04-11	North American Morning Briefing : Stock Futures -2-	DJ
04-10	KeyBanc Upgrades GoodRx to Overweight From Sector Weight on Increased Conviction Around Monthly Active Customers, Sets $9 Price Target	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

KeyBanc Upgrades GoodRx to Overweight From Sector Weight on Increased Conviction Around Monthly Active Customers, Sets $9 Price Target	04-10	MT
GoodRx Shares Jump Following Wells Fargo Upgrade, Price Target Boost	03-25	MT
Wells Fargo Upgrades GoodRx Holdings to Overweight From Equalweight, Adjusts Price Target to $10 From $7.50	03-25	MT
Deutsche Bank Adjusts GoodRx Price Target to $9 From $7, Maintains Hold Rating	03-04	MT
Goldman Sachs Raises GoodRx Holdings' Price Target to $7.50 From $6.50, Maintains Neutral Rating	03-01	MT
UBS Adjusts GoodRx Holdings Price Target to $8 From $5, Maintains Neutral Rating	03-01	MT
TD Cowen Adjusts Price Target on GoodRx Holdings to $14 From $12, Maintains Outperform Rating	03-01	MT
Truist Adjusts Price Target on GoodRx Holdings to $8 From $7.50, Maintains Hold Rating	03-01	MT
JPMorgan Adjusts GoodRx Holdings' Price Target to $7 From $6, Maintains Neutral Rating	03-01	MT
RBC Raises Price Target on GoodRx Holdings to $8 From $7, Keeps Sector Perform Rating	03-01	MT
Leerink Partners Initiates GoodRx Holdings at Outperform Rating With $8 Price Target	02-26	MT
Goldman Sachs Raises Price Target on GoodRx to $6.50 From $6, Maintains Neutral Rating	01-19	MT
RBC Raises Price Target on GoodRx Holdings to $7 From $5, Notes 'Positive Momentum,' Keeps Sector Perform Rating	01-16	MT
BofA Securities Downgrades GoodRx Holdings to Underperform From Buy, Adjusts Price Target to $4.50 From $8	01-02	MT
JPMorgan Trims Price Target on GoodRx Holdings to $6 From $7, Maintains Neutral Rating	11-17	MT
Goldman Sachs Trims Price Target on GoodRx Holdings to $6 From $7, Maintains Neutral Rating	11-10	MT
Truist Securities Adjusts Price Target on GoodRx Holdings to $5.50 From $8, Maintains Hold Rating	11-10	MT
UBS Adjusts GoodRx Price Target to $5 From $8, Maintains Neutral Rating	11-10	MT
Deutsche Bank Trims GoodRx Price Target to $7 From $8, Maintains Hold Rating	11-10	MT
Morgan Stanley Adjusts Price Target on GoodRx to $5.50 From $8, Maintains Equalweight Rating	11-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. GoodRx Holdings, Inc.

Equities

GDRX

US38246G1085

Analyst Reco.

Filters